Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai To Market Diabetic Neuropathic Pain Drug in China  

This article was originally published in PharmAsia News

Executive Summary

Eisai announced July 30 that its China subsidiary Eisai China entered a licensing agreement with Hong Kong-based Health Vision Enterprise, a sales subsidiary of STADA Arzneimittel AG for the sales and repackaging of alpha-lipon 300 STADA (alpha-lipoic acid), a treatment for diabetic neuropathic pain developed by STADA. Eisai China will take over sales promotion activities for the product starting August 1 and will assume repacking and sales rights upon receipt of approval. According to Eisai, diabetes patients in China increase annually by 10 percent and will reach 46 million by 2025. (Click here for more - Japanese language) "Eisai To Market Diabetes Complication Drug In China" - Search China News (7/30/08)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel